How to read FDA regulatory milestones: what each event changes—and what it does not

Your task as a reader: place every regulatory announcement into one of four buckets—permission to test, development alignment, application review, or marketing decision—then identify the remaining clinical, CMC, and execution risks.

Drugnews reading rule: a regulatory milestone reduces a specific uncertainty. It does not automatically validate every other part of the program. An IND can reduce near-term permission risk while leaving efficacy unknown; an accepted NDA can begin review while leaving approvability unresolved.

1. The four regulatory evidence states

1. Permission to test: the regulator allows a proposed clinical investigation to proceed.
2. Development alignment: sponsor and regulator discuss or agree on elements of the evidence plan.
3. Application review: a marketing application is being evaluated against efficacy, safety, CMC, inspection, and labeling requirements.
4. Marketing decision: the agency approves a defined use or issues an action explaining why the application is not ready for approval.

Most headline mistakes come from jumping across states: “FDA allowed the Phase I study” becomes “FDA endorsed the drug,” or “priority review” becomes “approval is likely.” The correct question is narrower: which uncertainty did this event actually reduce?

2. Milestone map: claim, evidence change, and residual risk

3. Permission to test is not an efficacy review

FDA states that the initial IND review period is 30 days. A sponsor may begin the investigation after FDA notifies it that the study may proceed or after 30 days if the IND is not placed on clinical hold.^[1] The initial review focuses on whether participants would face unreasonable risk and whether the submission contains the necessary clinical, nonclinical, and manufacturing information for the proposed study.

Therefore, “IND cleared” should be translated as the proposed trial may proceed, not FDA validated the mechanism. First-patient-dosed is another operational milestone: it confirms site activation and dosing, not recruitment speed, dose tolerance, proof of concept, or eventual registration.

A clinical hold is the mirror image. It may delay a proposed investigation or suspend an ongoing one. FDA can impose complete or partial holds, and the sponsor must address the stated basis before the affected study proceeds.^[2] The economic severity depends on the cause, scope, remedy, and effect on cash runway—not the word “hold” alone.

4. Development alignment reduces design risk, not outcome risk

FDA lists pre-IND, end-of-Phase I, end-of-Phase II/pre-Phase III, and pre-NDA/BLA meetings among Type B meetings.^[3] At EOP2, the sponsor can discuss whether the Phase III plan, endpoints, dose, safety database, and additional information appear capable of supporting a marketing application.

Alignment is valuable because it can prevent a company from running a well-executed trial that answers the wrong regulatory question. But meeting minutes are usually not public, and company language such as “FDA alignment” may compress qualifications, open issues, or commitments. Ask what was aligned:

• one endpoint or the whole pivotal program;
• trial design or approval pathway;
• clinical evidence or also CMC, device, companion diagnostic, and safety requirements;
• current assumptions or a binding agreement under defined conditions.

A Special Protocol Assessment can document agreement that a study design and planned analysis adequately address stated objectives. FDA correspondence also makes clear that final approval decisions follow review of the complete application and all submitted data.^[4] Protocol changes, execution failures, unexpected safety findings, or an inadequate product-quality package can still change the result.

5. Do not collapse four expedited programs into one

FDA distinguishes Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review because each operates at a different point and under different criteria.^[5]

• Fast Track facilitates development and review for serious conditions with unmet need. It can enable more frequent communication and rolling review.
• Breakthrough Therapy requires preliminary clinical evidence that the drug may offer substantial improvement on a clinically significant endpoint over available therapy. It strengthens development interaction; it is not approval.
• Accelerated Approval is an approval pathway based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, with confirmatory obligations.
• Priority Review is a review designation for a submitted marketing application; FDA describes a goal of action within six months.^[5]

Orphan Drug designation belongs to a different framework. It can provide incentives such as tax credits, user-fee waiver, and potential exclusivity upon approval, but the phrase upon approval matters.^[6] Orphan status should not be written as evidence that FDA has determined efficacy.

6. Read the application review as a sequence, not a binary event

Submission versus acceptance

A company controls when it announces an NDA or BLA submission. FDA then conducts a filing review. Acceptance means the application enters substantive review; it does not resolve whether efficacy, safety, CMC, inspections, labeling, or benefit–risk will support approval.

Priority Review and the PDUFA goal date

A PDUFA date is an agency action goal, not a promised approval date. The action can be an approval or a Complete Response Letter, and a major amendment can extend the review goal.^[7] A disciplined catalyst calendar therefore records both the target date and the possible action states.

Advisory committee

FDA advisory committees provide external scientific advice. Their recommendations are not binding; the final decision remains with FDA.^[8] The vote matters, but the questions, briefing documents, discussion of uncertainty, subgroup concerns, safety management, and proposed label can matter more than the final tally.

Complete Response Letter

FDA defines a CRL as notice that the review cycle is complete and the application is not ready for approval.^[9] That description is deliberately neutral. A CRL can involve clinical evidence, safety, CMC, facility inspections, device components, or labeling. Investors should avoid two opposite errors: calling every CRL a permanent failure, or calling every CMC-related CRL “only paperwork” without knowing whether new validation, inspection, manufacturing changes, or clinical bridging is required.

The next questions are: What deficiency was disclosed? Is a new trial required? Does remediation depend on a third-party manufacturer? What is the resubmission class and review timeline? How much cash and competitive time will be consumed?

7. Approval is exact—and pathway still matters

At approval, read the prescribing information and approval letter, not only the sponsor’s release. Record:

• the exact population, biomarker, stage, treatment line, and prior therapy;
• dose, route, schedule, titration, monitoring, and administration setting;
• contraindications, boxed warnings, safety monitoring, and discontinuation rules;
• whether approval is accelerated or traditional;
• postmarketing requirements, confirmatory studies, registries, or CMC commitments;
• whether a companion diagnostic or restricted-distribution program constrains use.

FDA’s Accelerated Approval program allows earlier approval based on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit. Confirmatory studies must verify the anticipated benefit; if they do not, FDA may pursue withdrawal or change the indication.^[10] Traditional approval does not mean “risk-free,” but it reflects a different evidentiary state.

8. Worked example: Leqembi moved from surrogate evidence to verified clinical benefit

Leqembi (lecanemab-irmb) illustrates why pathway and endpoint should be read together. FDA granted accelerated approval on January 6, 2023 based on reduction in amyloid beta plaques—a surrogate endpoint considered reasonably likely to predict clinical benefit. The approval required confirmation of benefit.^[11]

On July 6, 2023, FDA converted Leqembi to traditional approval after reviewing Study 301 (CLARITY AD), a randomized, double-blind, placebo-controlled trial in 1,795 patients with mild cognitive impairment or mild dementia stage Alzheimer’s disease and confirmed amyloid pathology. The primary endpoint was change from baseline in the Clinical Dementia Rating Scale–Sum of Boxes at 18 months.^[11]

FDA’s Drug Trials Snapshot reports adjusted mean change of 1.21 with Leqembi and 1.66 with placebo, a difference of −0.45, with p<0.0001.^[12] The sequence changed the evidence state:

1. Accelerated approval: marketing authorization based on plaque reduction as a surrogate, with residual uncertainty about clinical benefit.
2. Confirmatory trial: randomized evidence on cognitive and functional decline.
3. Traditional approval: FDA determined that the confirmatory evidence verified clinical benefit for the labeled population.

The conversion did not erase benefit–risk considerations. FDA’s approval communication highlighted amyloid-related imaging abnormalities and a boxed warning, including the possibility of serious or life-threatening events.^[11] The correct conclusion was not simply “approved twice.” The basis of approval moved from surrogate evidence to verified clinical benefit, while label-defined safety and monitoring remained central.

Defensible conclusion: a regulatory pathway tells you what evidence FDA accepted for a specific decision. To understand value, pair the pathway with the endpoint, label, confirmatory obligation, safety profile, and remaining operational constraints.

The catalyst-reading checklist

1. Exact event: sponsor submission, FDA permission, designation, meeting, filing acceptance, review goal, advisory vote, CRL, or approval?
2. Evidence state: permission to test, development alignment, application review, or marketing decision?
3. Scope: which indication, population, dose, formulation, geography, and trial?
4. Primary source: FDA page, approval letter, label, review document, meeting material, trial record, or only a company release?
5. Uncertainty reduced: safety-to-proceed, design, timing, efficacy, CMC, inspection, or labeling?
6. Residual risk: trial execution, effect size, safety, manufacturing, financing, reimbursement, or competition?
7. Next falsifiable event: first patient, data readout, submission, acceptance, inspection, AdCom, PDUFA action, resubmission, or confirmatory result?

Limits and uncertainty

FDA–sponsor correspondence and meeting minutes are often confidential, so public descriptions may omit qualifications. Regulatory policy also evolves, and another jurisdiction may use different procedures. Always check the dated FDA document, current label, and application-specific materials. This guide is educational and does not replace regulatory, legal, medical, or investment advice.

Primary sources

1. FDA — IND Applications for Clinical Investigations: Overview.
2. FDA — Submitting and Reviewing Complete Responses to Clinical Holds.
3. FDA — Product Application and Petition Review Process: types of sponsor meetings.
4. FDA — Example Special Protocol Assessment agreement and approval limitation.
5. FDA — Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review.
6. FDA — Rare Diseases and Orphan Products.
7. FDA — PDUFA Reauthorization Performance Goals and Procedures.
8. FDA — Advisory Committees: Critical to the Product Review Process.
9. FDA — Complete Response Letter Final Rule.
10. FDA — Accelerated Approval Program.
11. FDA — Leqembi conversion to traditional approval, July 6, 2023.
12. FDA — Drug Trials Snapshot: Leqembi.